Guerbet's Lipiodol Ultra Fluid Achieves EU Regulatory Milestone for Vascular Embolization Procedures

Key Takeaways

• Guerbet receives positive EU regulatory outcome for Lipiodol Ultra Fluid’s new vascular embolization indication through worksharing procedure
• New indication covers peripheral and central vascular embolization procedures using cyanoacrylate-based surgical glues for enhanced visualization
• Approval expands Lipiodol’s interventional radiology applications beyond traditional uses, potentially improving patient outcomes in vascular procedures

---

Guerbet Advances Lipiodol Ultra Fluid for Vascular Embolization

Guerbet, the global medical imaging leader, announced April 24, 2026, that it achieved a positive regulatory outcome from a European Union worksharing procedure for Lipiodol Ultra Fluid (iodinated ethyl esters of fatty acids of poppy seed oil) in vascular embolization procedures.

New Indication Expands Treatment Options

The regulatory milestone covers a new indication for interventional radiology procedures involving peripheral and central vascular embolization. Specifically, the approval allows Lipiodol Ultra Fluid to be used with cyanoacrylate-based surgical glues that are compatible with the contrast agent and approved for endovascular use.

This combination enables physicians to better visualize embolization procedures and make real-time adjustments during treatment, potentially improving procedural outcomes and patient safety.

Worksharing Procedure Streamlines EU Approval

The positive outcome resulted from a worksharing procedure involving several EU member states, which allows for coordinated regulatory review across multiple European markets simultaneously. This approach typically accelerates the approval process while maintaining rigorous safety and efficacy standards.

Market Impact and Clinical Significance

Lipiodol Ultra Fluid has been a established contrast agent in medical imaging, but this new vascular embolization indication represents a significant expansion into interventional procedures. Vascular embolization is a minimally invasive procedure used to block blood flow to specific areas, commonly employed in treating conditions like arteriovenous malformations, aneurysms, and certain tumors.

The ability to enhance visualization during these complex procedures could lead to improved precision and reduced procedural complications. For Guerbet, this regulatory success strengthens its position in the interventional radiology market and demonstrates the company’s commitment to expanding therapeutic applications for its imaging portfolio.

Looking Forward

This regulatory achievement positions Guerbet to capture additional market share in the growing interventional radiology sector, where demand for advanced imaging solutions continues to increase as minimally invasive procedures become more prevalent.

---

Frequently Asked Questions

What is Lipiodol Ultra Fluid used for in vascular embolization?

Lipiodol Ultra Fluid is used with cyanoacrylate-based surgical glues during peripheral and central vascular embolization procedures to provide enhanced visualization, allowing physicians to better see and adjust the procedure in real-time.

When will this new indication be available to patients?

While Guerbet announced the positive regulatory outcome in April 2026, the company has not yet specified the exact timeline for commercial availability across EU member states involved in the worksharing procedure.

How does this compare to existing vascular embolization methods?

This new indication enhances existing embolization procedures by providing better visualization when used with compatible cyanoacrylate glues, potentially improving procedural precision and safety compared to methods with limited real-time imaging capabilities.